Address And Details

P.O.Box 8528 , Boston, MA 02266
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

JPMorgan Emerging Markets Strategic Debt Fund seeks total return by investing in debt investments that it believes have the potential to provide total return from countries whose economies or bond markets are less developed (emerging markets).

Net Asset Value

as of 6:43 PM ET 09/17/2021

Performance

  • 1 Week
  • -0.12%
  • 1 Month
  • +1.00%
  • 3 Months
  • 0.00%
  • 1 Yr Return
  • +0.88%
  • 5 Yr Return
  • -2.30%

Equity Sector Breakdown

ConsumerDurables n/a
Energy n/a
Finance n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Bonds 96.72%
Other 1.90%
Cash 1.38%
Stocks 0.00%
Preferred 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 644.92 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -0.07 0.80 n/a
Beta 1.18 1.16 n/a
R Squared 0.12 0.16 n/a
Std Deviation 11.63 9.52 n/a
Sharpe Ratio 0.44 0.34 n/a

Purchase Information

as of 6:44 PM ET 09/16/2021
Minimum Initial $15000000
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 05/31/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 05/31/2021
1 Year
  • +5.42%
  • +11.94%
+5.42% +11.94%
3 Year
  • +5.49%
  • +4.57%
+5.49% +4.57%
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +0.22%
  • +0.01%
+0.22% +0.01%

Top 10 Holdings

Symbol Company Name % Of Assets
n/a

Recent Articles from TheStreet

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Stock Rises on Progress With Breast-Cancer Treatment

AstraZeneca's breast-cancer treatment reduced the risk of disease progression or death by 72% vs. a currently approved treatment.

Twitter Blue Lead

Twitter to Pay $810M to Settle Holder Suit Over User Engagement

Twitter's payment would settle a shareholder lawsuit that the company misled investors about its user engagement totals.

Starboard Takes Stake in CVS Health Corp.: Report

CVS to Add 25,000 Workers Ahead of Flu Season, Covid Booster Shots

Pharmacy giant CVS plans to add 25,000 ahead of flu season and coronavirus-related vaccinations.

Chinese Investors Mock Asset Managers And Offer Advice On Stock Picks For Cautious Approach To Renewables Sector

Stocks May Drop 20% as Stimulus Eases, Growth Slows: Morgan Stanley

Stocks could drop 20% as fiscal stimulus is withdrawn and economic growth slows, a Morgan Stanley strategist says.

Cryptocurrency Lead

Cryptocurrency Price Check: Bitcoin Tumbles on Evergrande Woes

Bitcoin and other cryptocurrencies are battered as China Evergrande Group struggles with bond obligations.

China Aims To Strengthen Its Semiconductor Supply Chain With New Standards Group That Includes Huawei, SMIC

Brooks Automation Stock Jumps on Plan to Sell Chip Solutions Unit for $3B

Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.

DR Horton, Verizon, HCA Holdings Top Analysts' Actions Monday

DR Horton Trims 2021 Sales Forecast Amid Supply Chain Disruptions

DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.

11. Colgate-Palmolive

Colgate-Palmolive Underappreciated, Deutsche Bank Says, Lifting to Buy

Colgate-Palmolive stock was upgraded to buy with an $86 price target at Deutsche Bank.

Watch Jim Cramer Live 9/20

Video: Jim Cramer on the Market Selloff, Evergrande, Debt Ceiling, Fed, Pfizer

Jim Cramer discusses the market selloff, Evergrande, debt ceiling talks, the upcoming Federal Reserve meeting, Pfizer and more in his latest video interview with TheStreet.

Wynn Lead

Wynn Resorts 'Worth Risk' of Macau Restrictions, Morgan Stanley Says

Wynn Resorts faces regulatory uncertainty in Macau, but Morgan Stanley says the casino operator is still 'worth the risk.'